ITM-22 is under clinical development by ITM Isotope Technologies Munich and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ITM-22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ITM-22 is under development for the treatment of prostate cancer. The therapeutic candidate comprises of tumor-targeting molecule (TTM) conjugated to radioligand actinium-225. It acts by targeting cells expressing prostate-specific membrane antigen (PSMA).
ITM Isotope Technologies Munich overview
ITM Isotope Technologies Munich (ITM) is a biotechnology company that develops and produces therapeutic and diagnostic radiopharmaceuticals and radioisotopes to treat cancer. Its product portfolio includes radiolabeling and quality control equipment includes iQS theranostics synthesizer, iQS Ga-68 fluidic labeling module and reagent set for manual labeling of NCA 177Lu and biomolecules. It also provides radiopharmaceuticals and medical radioisotopes includes endolucinbeta and TOCscan. ITM’s pipeline products include ITM-11 for neuroendocrine tumors (GEP-NETs); ITM-31 for glioblastoma; ITM-24D / ITM-22 for prostate cancer; ITM-55D and ITM-52 for ovarian cancer and NSCL adenocarcinoma; ITM-41 for osteosarcoma and bone metastases. It has laboratories manufacturing radiopharmaceuticals. ITM is headquartered in Munich, Bavaria, Germany.
For a complete picture of ITM-22’s drug-specific PTSR and LoA scores, buy the report here.